Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 10/20 | 1.00 |
| ▸ | PIN1 | Q13526 | 8/20 | 0.64 |
| ▸ | CDK1 | P06493 | 10/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.56 |
| ▸ | CDK2 | P24941 | 10/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomeguatrib SCHEMBL29406067 | 1.00 | MGMT (1.00) | MGMTPIN1CDK1CCNB1CCNA2 | |
| Lomeguatrib SCHEMBL19549802 | 0.80 | MGMT (0.67) | MGMTPIN1CDK1CCNB1CCNA2 | |
| Lomeguatrib SCHEMBL32671218 | 0.80 | MGMT (0.67) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL3302326 | 0.78 | PIN1 (1.00) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL8726745 | 0.77 | MGMT (0.62) | MGMTPIN1CDK2LMNACYP1A2 | |
| SCHEMBL3304633 | 0.75 | MGMT (0.60) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL3301829 | 0.73 | PIN1 (0.77) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL8618498 | 0.72 | CDK1 (0.77) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL30176198 | 0.72 | CDK1 (0.77) | MGMTPIN1CDK1CCNB1CCNA2 | |
| 6-O-Benzylguanine SCHEMBL31517079 | 0.72 | PIN1 (1.00) | MGMTPIN1CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135039-A1 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | FRED HUTCHINSON CANCER CENTER | 2025-05-01 | — | — | US | claimed |
| EP-4476331-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| US-20240368582-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | ENSOMA, INC. | 2024-11-07 | — | — | US | claimed |
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | claimed |
| EP-4319773-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | claimed |
| WO-2023150393-A2 | INHIBITOR-RESISTANT MGMT MODIFICATIONS AND MODIFICATION OF MGMT-ENCODING NUCLEIC ACIDS | ENSOMA, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230193350-A1 | METHOD FOR DIAGNOSING AND TREATING BLOOD CANCER | SAGA UNIVERSITY (JP) | 2023-06-22 | — | — | US | claimed |
| CN-116157529-A | Methods for identifying and/or modulating aging | 中国科学院动物研究所 | 2023-05-23 | — | — | CN | claimed |
| EP-4163379-A1 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | Institute Of Zoology, Chinese Academy Of Sciences (CN) | 2023-04-12 | — | — | EP | claimed |
| WO-2022216877-A1 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | ENSOMA, INC. (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022135486-A1 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | 中国科学院动物研究所 | 2022-06-30 | — | — | WO | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| US-12616750-B2 | Combination therapy utilizing DNA alkylating agents and ATR inhibitors | MERCK PATENT GMBH (DE) | 2026-05-05 | — | — | US | disclosed |
| EP-4719447-A2 | METHOD TO GENERATE INDUCED RETINAL PROGENITOR CELLS AND TREATMENT USING SUCH CELLS | Academia Sinica (TW) | 2026-04-08 | — | — | EP | disclosed |
| EP-4136262-B1 | PROGNOSIS METHOD OF ACUTE MYELOID LEUKAEMIA | CENTRE NAT RECH SCIENT (FR) | 2026-02-18 | — | — | EP | disclosed |
| WO-2005068465-A1 | 2-AMINO-O4-SUBSTITUTED PTERIDINES AND THEIR USE AS INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193350-A1 | METHOD FOR DIAGNOSING AND TREATING BLOOD CANCER | DUSP5, DUSP2, DUSP15 | MGMT 438/4885PIN1 2809/4885CDK1 846/4885 |
| US-12616750-B2 | Combination therapy utilizing DNA alkylating agents and ATR inhibitors | ATR, MRE11, CHEK2 | MGMT 159/4885PIN1 4240/4885CDK1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.